Highlights and Quick Summary
- Consolidated Net Income/Loss for the quarter ending December 30, 2019 was $2.8 Billion (a 48.67% increase compared to previous quarter)
- Year-over-year quarterly Consolidated Net Income/Loss increased by 14.05%
- Annual Consolidated Net Income/Loss for 2019 was $7.88 Billion (a 38.6% increase from previous year)
- Annual Consolidated Net Income/Loss for 2018 was $5.69 Billion (a 7.12% increase from previous year)
- Annual Consolidated Net Income/Loss for 2017 was $5.31 Billion (a -10.82% decrease from previous year)
- Twelve month Consolidated Net Income/Loss ending December 30, 2019 was $7.88 Billion (a 142.15% increase compared to previous quarter)
- Twelve month trailing Consolidated Net Income/Loss increased by 47.05% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
| 30 Dec '19 | 29 Sep '19 | 29 Jun '19 | 30 Mar '19 |
|---|---|---|---|
| $7.88 Billion | $3.26 Billion | $4.12 Billion | $5.36 Billion |
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Consolidated Net Income/Loss of AbbVie Inc.
Most recent Consolidated Net Income/Lossof ABBV including historical data for past 10 years.Interactive Chart of Consolidated Net Income/Loss of AbbVie Inc.
AbbVie Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2019 | $2,801.0 | $1,884.0 | $741.0 | $2,456.0 | $7,882.0 |
| 2018 | $-1,826.0 | $2,747.0 | $1,983.0 | $2,783.0 | $5,687.0 |
| 2017 | $52.0 | $1,631.0 | $1,915.0 | $1,711.0 | $5,309.0 |
| 2016 | $1,391.0 | $1,598.0 | $1,610.0 | $1,354.0 | $5,953.0 |
| 2015 | $1,517.0 | $1,239.0 | $1,366.0 | $1,022.0 | $5,144.0 |
| 2014 | $-810.0 | $506.0 | $1,098.0 | $980.0 | $1,774.0 |
| 2013 | $1,128.0 | $964.0 | $1,068.0 | $968.0 | $4,128.0 |
| 2012 | $1,540.0 | $1,585.0 | $1,267.0 | $883.0 | $5,275.0 |
| 2011 | $1,157.0 | $13.0 | $1,540.0 | $723.2 | $3,433.0 |
| 2010 | – | – | – | – | $4,178.0 |
| 2009 | – | – | – | – | $4,636.52 |
Business Profile of AbbVie Inc.
Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.